Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares OutstandingShort-Term Debt repayments
Ratios

Palisade Bio (PALI) Receivables - Net (2016 - 2023)

Palisade Bio has reported Receivables - Net over the past 12 years, most recently at $300000.0 for Q1 2023.

  • Quarterly Receivables - Net changed N/A to $300000.0 in Q1 2023 from the year-ago period, while the trailing twelve-month figure was $300000.0 through Mar 2023, changed N/A year-over-year, with the annual reading at $59000.0 for FY2020, 180.1% up from the prior year.
  • Receivables - Net was $300000.0 for Q1 2023 at Palisade Bio, up from $59000.0 in the prior quarter.
  • Over five years, Receivables - Net peaked at $300000.0 in Q1 2023 and troughed at $8779.0 in Q3 2020.
  • The 4-year median for Receivables - Net is $59000.0 (2020), against an average of $88899.5.
  • Year-over-year, Receivables - Net tumbled 92.84% in 2019 and then skyrocketed 248.33% in 2021.
  • A 4-year view of Receivables - Net shows it stood at $21064.0 in 2019, then soared by 180.1% to $59000.0 in 2020, then changed by 0.0% to $59000.0 in 2021, then soared by 408.47% to $300000.0 in 2023.
  • Per Business Quant, the three most recent readings for PALI's Receivables - Net are $300000.0 (Q1 2023), $59000.0 (Q2 2021), and $25259.0 (Q1 2021).